Group-based pharmacogenetic prediction: is it feasible and do current NHS England ethnic classifications provide appropriate data?
- 18 July 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in The Pharmacogenomics Journal
- Vol. 21 (1), 47-59
- https://doi.org/10.1038/s41397-020-0175-0
Abstract
Inter-individual variation of drug metabolising enzymes (DMEs) leads to variable efficacy of many drugs and even adverse drug responses. Consequently, it would be desirable to test variants of many DMEs before drug treatment. Inter-ethnic differences in frequency mean that the choice of SNPs to test may vary across population groups. Here we examine the utility of testing representative groups as a way of assessing what variants might be tested. We show that publicly available population information is potentially useful for determining loci for pre-treatment genetic testing, and for determining the most prevalent risk haplotypes in defined groups. However, we also show that the NHS England classifications have limitations for grouping for these purposes, in particular for people of African descent. We conclude: (1) genotyping of hospital patients and people from the hospital catchment area confers no advantage over using samples from appropriate existing ethnic group collections or publicly available data, (2) given the current NHS England Black African grouping, a decision as to whether to test, would have to apply to all patients of recent Black African ancestry to cover reported risk alleles and (3) the current scarcity of available genome and drug effect data from Africans is a problem for both testing and treatment decisions.Funding Information
- University College London Hospitals Comprehensive Biomedical Research Centre.
This publication has 46 references indexed in Scilit:
- Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C19 Genotype and Clopidogrel Therapy: 2013 UpdateClinical Pharmacology & Therapeutics, 2013
- African variation at Cytochrome P450 genesEvolution, Medicine, and Public Health, 2013
- MaravirocDrugs, 2010
- Fulfilling the Promise of Personalized Medicine? Systematic Review and Field Synopsis of Pharmacogenetic StudiesPLOS ONE, 2009
- Adverse Drug Reactions in Hospital In-Patients: A Prospective Analysis of 3695 Patient-EpisodesPLOS ONE, 2009
- Human Flavin-Containing Monooxygenase 2.1 Catalyzes Oxygenation of the Antitubercular Drugs Thiacetazone and EthionamideDrug Metabolism and Disposition, 2008
- Carbamazepine, HLA-B*1502 and risk of Stevens–Johnson syndrome and toxic epidermal necrolysis: US FDA recommendationsPharmacogenomics, 2008
- The potentially deleterious functional variant flavin-containing monooxygenase 2*1 is at high frequency throughout sub-Saharan AfricaPharmacogenetics and Genomics, 2008
- African Genetic Diversity: Implications for Human Demographic History, Modern Human Origins, and Complex Disease MappingAnnual Review of Genomics and Human Genetics, 2008
- Pharmacogenetics of Oral AnticoagulantsClinical Pharmacokinetics, 2008